1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
(
- Contribution to journal › Article
-
Mark
Acupuncture for Nocturia in Survivors of Prostate Cancer : The NOCTURNAL Randomized Clinical Trial
(
- Contribution to journal › Article
-
Mark
Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing
2025) In JAMA Oncology(
- Contribution to journal › Article
- 2024
-
Mark
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Longer Interval Between First Colonoscopy With Negative Findings for Colorectal Cancer and Repeat Colonoscopy
(
- Contribution to journal › Article
- 2023
-
Mark
External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups
(
- Contribution to journal › Article
- 2022
-
Mark
Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer
(
- Contribution to journal › Article
-
Mark
Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes
(
- Contribution to journal › Article
- 2021
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer-Reply
(
- Contribution to journal › Letter